Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-3: palbociclib plus fulvestrant versus placebo plus fulvestrant in HR-positive/HER2-negative metastatic breast cancer after endocrine progression
NL-OMON50735Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palbociclib, fulvestrant and goserelin in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Feb 2014; status: active, not recruiting.
02
Drugs
palbociclibfulvestrantgoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON50735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50735.